The ELISA mouse VEGF-B test quantified mouse VEGF-B in serum, plasma or cell culture medium. The dosage will recognize only natural and recombinant MEGF-B. Principle of the L-L-ELISA method...
The ELISA mouse VEGF-B test quantified mouse VEGF-B in serum, plasma or cell culture medium. The assay will recognize only natural and recombinant MEGF-B. Principle of the L-ELISA solid phase sandwich method of mouse VEGF-B (enzymatic immunoassay) is designed to measure the amount of the target bound between a pair of matched antibodies. A target-specific antibody was pre-vested in the wells of the supplied microplate. Samples, standards or controls are then added to these wells and bound to immobilized antibody (capture). The sandwich is formed by adding the second antibody (detector), a substrate solution that reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.
Vascular endothelial growth factors (VEGF) are a family of closely related growth factors with a preserved model of eight cysteine residues and sharing common VEGF receptors. VEGF stimulates endothelial cells, induces angiogenesis, promotes cell migration, increases vascular permeability and inhibits apoptosis. VEGFB has structural similarities with VEGF and PIGF and is frequently co-expressed with VEGF. There are two isoforms of VEGFB with alternative splicing: VEGFB 167 and VEGFB 186. The VEGFB 167, a highly basic protein binding heparin, remains with the extracellular cell or matrix while the VEGFB 186 is easily secreted. VEGFB stimulates endothelial cell proliferation. VEGFB binds to the tyrosine kinase receptor VEGFR1 (flt1) and does not bind to VEGFR2. The vascular endothelial growth factor B is widely expressed but is most abundant in the heart, skeletal muscles, and pancreas. It has been suggested that expression of VEGFB in human primary breast cancers is associated with metastasis of lymph nodes. The genes encoding VEGFB were mapped on chromosome 11q13.
Sensitivity
Sensitivity of dosage: 0.6 ng/ml.
Measurement range
Dose range: 0.655 to 160 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Samples
Sample volume: Plasma, 50 µl; serum, 50 µl; supernatant, 100 µl.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17165799 |
| Specifications |
| Accession number | Vascular endothelial growth factor B; VEGFB; VEGF-B; VEGFL; VEGF factor; VRF |
| Dose range | 0.655 to 160 pg/ml |
| Sensitivity of the dosage | 0.6 ng/ml |
| Conjugate | Biotin |
| Product type | ELISA |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | P49766 |
| Gene symbol(s) | VEGFB |
| Coefficient of inter-dose variation | <12% |
| Coefficient of intra-dose variation | <10% |
| Contents of kits | 96-well pre-coated plate Standard Concentrate of dosing diluent Biotinylated detection antibody SAV-HRP Wash pad Chromogen Discontinue solution Adhesive plate covers |
| Marker or dye | HRP |
| Quantity | 5 x 96 tests |
| Regulatory status | Use exclusively for research |
| Target | VEGFB |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Plasma, 50 µl; serum, 50 µl; supernatant, 100 µl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | EMVEGFBX5 |
|---|
| Country of origin | United States |
|---|
A question or a specific configuration?
Contact us for a quote.